Immuneering Shares Are Trading Lower After the Company Announced Topline Result From the Ongoing Phase 1 Portion of Its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced RAS-mutant Solid Tumors
Immuneering的股價走低,此前該公司公佈了正在進行的針對晚期 RAS-突變實體瘤的 IMM-1-104 1/2a 期臨床試驗 1 期的總體結果